Export financials
Sintx Technologies (SINT)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.

Sintx Technologies Cash Flow 2025-2011 | SINT
Brief cash flow overview of Sintx Technologies
The comparison covers five available annual reports between 2021 and 2025.
Cash from operations is below zero at -$8.6 million, increasing dependence on cash reserves or outside financing.
Only 0 of five annual observations were positive, indicating weak repeatability.
Receivables and inventory net of payables grew by $163 thousand, absorbing resources equal to about 16% of revenue.
What the cash flows show
Taken together, Sintx Technologies's cash flow indicators point to increased dependence on reserves or outside financing.
Annual Cash Flow Sintx Technologies
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
-8.57 M | -8.64 M | -14.1 M | -10.3 M | -10.1 M | -9.11 M | -6.44 M | -9.35 M | -4.68 M | -7.17 M | -9.06 M | -14.5 M | - | - | - |
Depreciation & Amortization |
319 K | 842 K | 907 K | 335 K | 185 K | 78 K | 102 K | 105 K | 105 K | 1.44 M | 1.65 M | 1.84 M | 1.71 M | - | - |
Accounts Payables |
382 K | 299 K | 636 K | 434 K | 241 K | 194 K | 191 K | 301 K | 1.73 M | 658 K | 643 K | 778 K | - | - | - |
Accounts Receivables |
178 K | 196 K | 685 K | 328 K | 102 K | 41 K | 136 K | 263 K | 1.24 M | 1.62 M | 2.66 M | 2.51 M | - | - | - |
Total Inventories |
825 K | 502 K | 888 K | 737 K | 597 K | 487 K | 639 K | 624 K | 2.38 M | 7.21 M | 9.13 M | 11.7 M | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Cash Flow Sintx Technologies
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
- | -2.77 M | -2.49 M | -2.34 M | -2.52 M | -2.41 M | -1.3 M | -1.12 M | -2.57 M | -2.22 M | -2.73 M | -3.13 M | -2.92 M | -3.2 M | -4.87 M | -2.08 M | -2.46 M | -2.54 M | -3.18 M | -2.38 M | -2.41 M | -2.35 M | -2.99 M | -2.06 M | -2.12 M | -1.54 M | -3.4 M | -1.56 M | -1.55 M | -1.63 M | -1.7 M | - | -7.95 M | -5.93 M | -2.08 M | -284 K | -4.4 M | -3.43 M | -1.83 M | - | -5.26 M | -2.38 M | -1.46 M | - | -7.06 M | -5.32 M | -2.97 M | - | -11.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Depreciation & Amortization |
- | 9 K | 8 K | 8 K | 8 K | 2 K | 1 K | 1 K | 2 K | 1 K | 1 K | 1 K | 1 K | 2 K | 1 K | 1 K | 1 K | 2 K | 1 K | 2 K | 1 K | 1 K | 1 K | 1 K | 2 K | 1 K | 1 K | 1 K | 2 K | 1 K | 1 K | - | 75 K | 53 K | 26 K | 134 K | - | 293 K | 162 K | - | 1.12 M | 772 K | 389 K | - | 1.26 M | 841 K | 428 K | - | 1.37 M | 897 K | 433 K | - | 1.29 M | 890 K | 510 K | - | - | - | - | - | - | - | - |
Accounts Payables |
1.7 M | 934 K | 571 K | 382 K | 203 K | 183 K | 438 K | 299 K | 153 K | 331 K | 448 K | 636 K | 481 K | 502 K | 486 K | 434 K | 289 K | 372 K | 490 K | 241 K | 169 K | 154 K | 397 K | 194 K | 157 K | 96 K | 173 K | 191 K | 166 K | 295 K | 254 K | 301 K | 301 K | 301 K | 301 K | 1.73 M | 1.16 M | 1.73 M | 1.73 M | 658 K | 658 K | 658 K | 658 K | 643 K | 643 K | 643 K | 643 K | 778 K | 778 K | 778 K | 778 K | 3.38 M | 3.38 M | 3.38 M | 3.38 M | - | - | - | - | - | - | - | - |
Accounts Receivables |
131 K | 329 K | 364 K | 178 K | 120 K | 97 K | 97 K | 196 K | 340 K | 434 K | 483 K | 685 K | 259 K | 385 K | 467 K | 328 K | 230 K | 268 K | 106 K | 102 K | 182 K | 29 K | 67 K | 41 K | 49 K | 60 K | 106 K | 136 K | 113 K | 173 K | 45 K | 263 K | 1.2 M | 263 K | 263 K | 1.24 M | 1.59 M | 1.24 M | 1.24 M | 1.62 M | 1.62 M | 1.62 M | 1.62 M | 2.66 M | 2.66 M | 2.66 M | 2.66 M | 2.51 M | 2.51 M | 2.51 M | 2.51 M | 2.82 M | 2.82 M | 2.82 M | 2.82 M | - | - | - | - | - | - | - | - |
Total Inventories |
2.56 M | 2.25 M | 1.39 M | 825 K | 447 K | 355 K | 425 K | 502 K | 463 K | 1.02 M | 1.18 M | 888 K | 1.06 M | 883 K | 626 K | 737 K | 749 K | 775 K | 624 K | 597 K | 690 K | 754 K | 515 K | 487 K | 535 K | 659 K | 712 K | 639 K | 711 K | 596 K | 665 K | 676 K | 676 K | 624 K | 624 K | 675 K | 5.67 M | 2.38 M | 2.38 M | 7.21 M | 7.21 M | 7.21 M | 7.21 M | 9.13 M | 9.13 M | 9.13 M | 9.13 M | 11.7 M | 11.7 M | 11.7 M | 11.7 M | 10.1 M | 10.1 M | 10.1 M | 10.1 M | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Cash Flow Statement is one of the three key financial reports of the company Sintx Technologies, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.
Main Sections of the Cash Flow Statement- Operating Activities
This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash. - Investing Activities
Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign. - Financing Activities
Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.
The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.
Cash flow statements of other stocks in the Medical devices sector
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
Conformis
CFMS
|
- | - | $ 16.4 M | ||
|
ViewRay
VRAY
|
- | 1.54 % | $ 468 M | ||
|
Medigus Ltd.
MDGS
|
- | 10.28 % | $ 55.5 M | ||
|
Abbott Laboratories
ABT
|
$ 103.08 | -0.98 % | $ 179 B | ||
|
Align Technology
ALGN
|
$ 154.77 | -3.07 % | $ 11.2 B | ||
|
Vapotherm
VAPO
|
- | 6.72 % | $ 34 M | ||
|
Silk Road Medical, Inc
SILK
|
- | - | $ 1.07 B | ||
|
Alphatec Holdings
ATEC
|
$ 6.66 | -3.48 % | $ 999 M | ||
|
Boston Scientific Corporation
BSX
|
$ 41.95 | -2.43 % | $ 62.1 B | ||
|
Natus Medical Incorporated
NTUS
|
- | 1.94 % | $ 1.05 B | ||
|
Nemaura Medical
NMRD
|
- | -17.8 % | $ 2.74 M | ||
|
Butterfly Network
BFLY
|
$ 5.39 | -8.28 % | $ 1.33 B | ||
|
Bio-Rad Laboratories
BIO
|
$ 358.56 | -2.43 % | $ 9.78 B | ||
|
Edwards Lifesciences Corporation
EW
|
$ 101.86 | -1.94 % | $ 59.6 B | ||
|
Aethlon Medical
AEMD
|
$ 5.49 | 13.33 % | $ 3.7 M | ||
|
Apyx Medical Corporation
APYX
|
$ 2.39 | 2.06 % | $ 98.2 M | ||
|
Cognyte Software Ltd.
CGNT
|
$ 7.27 | -6.56 % | $ 530 M | ||
|
Medtronic PLC
MDT
|
$ 99.64 | -1.0 % | $ 128 B | ||
|
Myomo
MYO
|
$ 0.81 | -3.74 % | $ 33.9 M | ||
|
Establishment Labs Holdings
ESTA
|
$ 69.2 | -0.59 % | $ 2.05 B | ||
|
Insulet Corporation
PODD
|
$ 133.09 | -3.02 % | $ 9.36 B | ||
|
Profound Medical Corp.
PROF
|
$ 6.39 | -3.03 % | $ 193 M | ||
|
Integer Holdings Corporation
ITGR
|
$ 126.97 | -0.01 % | $ 4.41 B | ||
|
Delcath Systems
DCTH
|
$ 18.77 | -2.44 % | $ 672 M | ||
|
Electromed
ELMD
|
$ 23.03 | -1.46 % | $ 190 M | ||
|
Inogen
INGN
|
$ 5.3 | -2.31 % | $ 141 M | ||
|
Globus Medical
GMED
|
$ 66.85 | -2.55 % | $ 9.04 B | ||
|
IRadimed Corporation
IRMD
|
$ 81.04 | -0.25 % | $ 1.03 B | ||
|
Penumbra
PEN
|
$ 319.13 | -0.27 % | $ 12.4 B | ||
|
Smith & Nephew plc
SNN
|
$ 29.85 | 0.05 % | $ 25.9 B | ||
|
ClearPoint Neuro
CLPT
|
$ 6.91 | -5.47 % | $ 196 M | ||
|
Sensus Healthcare
SRTS
|
$ 2.28 | -3.39 % | $ 37.2 M | ||
|
Accuray Incorporated
ARAY
|
$ 2.1 | -1.18 % | $ 258 M | ||
|
Stryker Corporation
SYK
|
$ 309.41 | -1.24 % | $ 118 B | ||
|
AxoGen
AXGN
|
$ 55.74 | -1.08 % | $ 2.57 B | ||
|
Tactile Systems Technology
TCMD
|
$ 25.62 | -1.42 % | $ 586 M | ||
|
Quanterix Corporation
QTRX
|
$ 1.95 | -3.94 % | $ 83.1 M | ||
|
TELA Bio
TELA
|
$ 0.69 | -4.9 % | $ 32.4 M | ||
|
IRIDEX Corporation
IRIX
|
$ 0.45 | -4.57 % | $ 7.62 M | ||
|
Cytosorbents Corporation
CTSO
|
$ 4.37 | -14.76 % | $ 272 M | ||
|
TransMedics Group
TMDX
|
$ 85.17 | -9.42 % | $ 2.9 B | ||
|
Integra LifeSciences Holdings Corporation
IART
|
$ 13.25 | -2.21 % | $ 1.02 B | ||
|
Nano-X Imaging Ltd.
NNOX
|
$ 0.23 | -2.13 % | $ 14.9 M | ||
|
Tandem Diabetes Care
TNDM
|
$ 17.2 | 2.35 % | $ 1.17 B | ||
|
Bruker Corporation
BRKR
|
$ 56.41 | -9.17 % | $ 8.56 B |